This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Esparza, J. Articles by Osmanov, S. Search for Related Content Social Bookmarking                         What's this?

Current Issues in HIV Vaccine Development

World Health Organisation, 20 Avenue Appia, 1211 Geneva 27, Switzerland E-mail: esparzaj{at}who.ch.

Saladin Osmanov

World Health Organisation, 20 Avenue Appia, 1211 Geneva 27, Switzerland,

An HIV preventive vaccine constitutes the best long-term hope to control the HIV/ AIDS pandemic. A number of scientific challenges must be addressed before a vaccine is developed. An important issue to be solved relates to the significance of the HIV genetic variability in terms of potential vaccine-induced protection. Since 1987 more than 30 different candidate vaccines have been tested in more than 6,000 healthy human volunteers. Most of these trials have been conducted in the United States and Europe, and also in developing countries. The first Phase III efficacy trials were initiated in 1998 and 1999 in the United States and Thailand, and the initial results will be available at the end of 2001. To accelerate vaccine development it is important to conduct multiple trials to simultaneously evaluate several types of vaccines, against different HIV subtypes, in diverse populations. Developing countries must strengthen their infrastructures to be able to conduct trials of the highest scientific and ethical standards.

Journal of Health Management, Vol. 2, No. 2, 245-255 (2000)
DOI: 10.1177/097206340000200209


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?